Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Patients
2.2. Study Endpoints
2.3. Statistical Analysis
3. Results
3.1. Patients
3.2. Characterization of LLT Use and Changes
3.3. Achievement of Risk-Based LDL-C Goals
3.4. Factors Associated with LDL-C Goal Attainment
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [Google Scholar] [CrossRef] [PubMed]
- Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017, 38, 2459–2472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cholesterol Treatment Trialists, C.; Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376, 1670–1681. [Google Scholar] [CrossRef] [Green Version]
- Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020, 41, 111–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366, 1267–1278. [Google Scholar] [CrossRef]
- Garcia-Gil, M.; Blanch, J.; Comas-Cufi, M.; Daunis-i-Estadella, J.; Bolibar, B.; Marti, R.; Ponjoan, A.; Alves-Cabratosa, L.; Ramos, R. Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical records. J. Clin. Lipidol. 2016, 10, 134–142. [Google Scholar] [CrossRef] [Green Version]
- Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; McCagg, A.; White, J.A.; Theroux, P.; Darius, H.; Lewis, B.S.; Ophuis, T.O.; Jukema, J.W.; et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015, 372, 2387–2397. [Google Scholar] [CrossRef] [Green Version]
- Mensah, G.A.; Wei, G.S.; Sorlie, P.D.; Fine, L.J.; Rosenberg, Y.; Kaufmann, P.G.; Mussolino, M.E.; Hsu, L.L.; Addou, E.; Engelgau, M.M.; et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ. Res. 2017, 120, 366–380. [Google Scholar] [CrossRef]
- Moran, A.E.; Forouzanfar, M.H.; Roth, G.A.; Mensah, G.A.; Ezzati, M.; Murray, C.J.; Naghavi, M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global Burden of Disease 2010 study. Circulation 2014, 129, 1483–1492. [Google Scholar] [CrossRef] [Green Version]
- De Backer, G.; Jankowski, P.; Kotseva, K.; Mirrakhimov, E.; Reiner, Z.; Ryden, L.; Tokgozoglu, L.; Wood, D.; De Bacquer, D.; EUROASPIRE V Collaborators; et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019, 285, 135–146. [Google Scholar] [CrossRef] [Green Version]
- Santos, R.D. Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. Eur. J. Prev. Cardiol. 2019, 26, 820–823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gomez-Barrado, J.J.; Ortiz, C.; Gomez-Turegano, M.; Gomez-Turegano, P.; Garciperez-de-Vargas, F.J.; Sanchez-Calderon, P. Lipid control in patients with coronary artery disease in a healthcare area in Caceres (Spain): LIPICERES study. Clin. Investig. Arterioscler. 2017, 29, 13–19. [Google Scholar] [CrossRef] [PubMed]
- Gomez-Barrado, J.J.; Gomez-Turegano, P.; Ortiz-Cortes, C.; Vega-Fernandez, J.; Gomez-Turegano, M.; Garciperez de Vargas, F.J.; Lezcano Gort, L.E.; Kounka, Z.; Roque Rodriguez, B.; Chipayo Gonzales, D.; et al. Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry. Cardiol. Res. 2020, 11, 311–318. [Google Scholar] [CrossRef]
- Anguita Sanchez, M.; Gomez Doblas, J.J.; Barrios Alonso, V. Control of LDL-C levels after an acute coronary syndrome in Spain. Are the available treatments adequately used? Revista Española de Cardiología 2021, 74, 194–196. [Google Scholar] [CrossRef] [PubMed]
- Galve, E.; Cordero, A.; Cequier, A.; Ruiz, E.; González-Juanatey, J. Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. Revista Española de Cardiología 2016, 69, 931–938. [Google Scholar] [CrossRef]
- Guallar-Castillon, P.; Gil-Montero, M.; Leon-Munoz, L.M.; Graciani, A.; Bayan-Bravo, A.; Taboada, J.M.; Banegas, J.R.; Rodriguez-Artalejo, F. Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008-2010: The ENRICA StudyRev. Revista Española de Cardiología 2012, 65, 551–558. [Google Scholar] [CrossRef]
- Barrios, V.; Soronen, J.; Carter, A.M.; Anastassopoulou, A. Lipid management across Europe in the real-world setting: A rapid evidence review. Curr. Med. Res. Opin. 2021, 37, 2049–2059. [Google Scholar] [CrossRef]
- Banegas, J.R.; Lopez-Garcia, E.; Dallongeville, J.; Guallar, E.; Halcox, J.P.; Borghi, C.; Masso-Gonzalez, E.L.; Jimenez, F.J.; Perk, J.; Steg, P.G.; et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: The EURIKA study. Eur. Heart J. 2011, 32, 2143–2152. [Google Scholar] [CrossRef]
- Danchin, N.; Almahmeed, W.; Al-Rasadi, K.; Azuri, J.; Berrah, A.; Cuneo, C.A.; Karpov, Y.; Kaul, U.; Kayikcioglu, M.; Mitchenko, O.; et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur. J. Prev. Cardiol. 2018, 25, 1087–1094. [Google Scholar] [CrossRef] [Green Version]
- Group, E.I.S. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. 2001, 22, 554–572. [Google Scholar] [CrossRef] [Green Version]
- Kristensen, M.S.; Green, A.; Nybo, M.; Hede, S.M.; Mikkelsen, K.H.; Gislason, G.; Larsen, M.L.; Ersboll, A.K. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: A Danish population-based cohort study. BMC Cardiovasc. Disord. 2020, 20, 336. [Google Scholar] [CrossRef] [PubMed]
- Mostafa, S.A.; Elrabat, K.; Mahrous, M.; Kamal, M. Short term comparison between safety and efficacy of rosuvastatin 40 mg and atorvastatin 80 mg in patients with acute coronary syndrome. Ration. Pharmacother. Cardiol. 2018, 14, 636–645. [Google Scholar] [CrossRef]
- Perez de Isla, L.; Saltijeral Cerezo, A.; Vitale, G.; Gonzalez Timon, B.; Torres Do Rego, A.; Alvarez-Sala Walther, L.A. Prevalence of inapropriate LDL cholesterol levels in patients with coronary disease and/or type 2 diabetes. Rev. Clin. Esp. 2012, 212, 475–481. [Google Scholar] [CrossRef]
- Stein, B.; Ward, T.; Hale, G.; Lyver, E. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg. Ann. Pharm. 2020, 54, 405–413. [Google Scholar] [CrossRef]
- Shin, J.; Lim, H.; Kim, H.S. Long-term change in the target achievement rate of low-density lipoprotein cholesterol in patients with cardiovascular disease. Int. J. Clin. Pharmacol. Ther. 2023, 61, 159–171. [Google Scholar] [CrossRef]
- Talic, S.; Marquina, C.; Zomer, E.; Ofori-Asenso, R.; Petrova, M.; Vargas-Torres, S.; Abushanab, D.; Wolfe, R.; Lybrand, S.; Thomson, D.; et al. Attainment of low-density lipoprotein cholesterol goals in statin treated patients: Real-world evidence from Australia. Curr. Probl. Cardiol. 2022, 47, 101068. [Google Scholar] [CrossRef]
- Vrablik, M.; Seifert, B.; Parkhomenko, A.; Banach, M.; Jozwiak, J.J.; Kiss, R.G.; Gaita, D.; Raslova, K.; Zachlederova, M.; Bray, S.; et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021, 334, 66–75. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Leor, O.; Cid-Alvarez, B.; Perez de Prado, A.; Rossello, X.; Ojeda, S.; Serrador, A.; Lopez-Palop, R.; Martin-Moreiras, J.; Rumoroso, J.R.; Cequier, A.; et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Revista Española de Cardiología 2020, 73, 994–1002. [Google Scholar] [CrossRef] [PubMed]
- Lau, D.; McAlister, F.A. Implications of the COVID-19 Pandemic for Cardiovascular Disease and Risk-Factor Management. Can. J. Cardiol. 2021, 37, 722–732. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Juanatey, J.R.; Millan, J.; Alegria, E.; Guijarro, C.; Lozano, J.V.; Vitale, G.C. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study. Rev. Esp. Cardiol. 2011, 64, 286–294. [Google Scholar] [CrossRef]
- Chiang, C.E.; Ferrieres, J.; Gotcheva, N.N.; Raal, F.J.; Shehab, A.; Sung, J.; Henriksson, K.M.; Hermans, M.P. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J. Atheroscler. Thromb. 2016, 23, 567–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, J.H.; Cha, J.J.; Lim, S.; An, J.; Kim, M.N.; Hong, S.J.; Joo, H.J.; Park, J.H.; Yu, C.W.; Lim, D.S.; et al. Target Low-Density Lipoprotein-Cholesterol and Secondary Prevention for Patients with Acute Myocardial Infarction: A Korean Nationwide Cohort Study. J. Clin. Med. 2022, 11, 2650. [Google Scholar] [CrossRef]
- Presta, V.; Figliuzzi, I.; Miceli, F.; Coluccia, R.; Fogacci, F.; Cicero, A.F.G.; Ferrucci, A.; Borghi, C.; Volpe, M.; Tocci, G.; et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis 2019, 285, 40–48. [Google Scholar] [CrossRef]
- Marquina, C.; Talic, S.; Zomer, E.; Vargas-Torres, S.; Petrova, M.; Wolfe, R.; Abushanab, D.; Lybrand, S.; Thomson, D.; Stratton, G.; et al. Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care. J. Clin. Lipidol. 2022, 16, 498–507. [Google Scholar] [CrossRef]
- Ito, M.K.; Watts, G.F. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Drugs 2015, 75, 1715–1724. [Google Scholar] [CrossRef] [Green Version]
- Iyen, B.; Akyea, R.K.; Weng, S.; Kai, J.; Qureshi, N. Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. Open Heart 2021, 8, e001817. [Google Scholar] [CrossRef] [PubMed]
- Perez de Isla, L.; Alonso, R.; Watts, G.F.; Mata, N.; Saltijeral Cerezo, A.; Muniz, O.; Fuentes, F.; Diaz-Diaz, J.L.; de Andres, R.; Zambon, D.; et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J. Am. Coll. Cardiol. 2016, 67, 1278–1285. [Google Scholar] [CrossRef]
- Gitt, A.K.; Lautsch, D.; Ferrieres, J.; De Ferrari, G.M.; Vyas, A.; Baxter, C.A.; Bash, L.D.; Ashton, V.; Horack, M.; Almahmeed, W.; et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017, 266, 158–166. [Google Scholar] [CrossRef] [PubMed]
- Perez-Calahorra, S.; Laclaustra, M.; Marco-Benedi, V.; Pinto, X.; Sanchez-Hernandez, R.M.; Plana, N.; Ortega, E.; Fuentes, F.; Civeira, F. Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids. Health Dis. 2019, 18, 216. [Google Scholar] [CrossRef] [Green Version]
- Silverman, M.G.; Ference, B.A.; Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016, 316, 1289–1297. [Google Scholar] [CrossRef] [Green Version]
- Arca, M.; Pigna, G. Treating statin-intolerant patients. Diabetes Metab. Syndr. Obes. 2011, 4, 155–166. [Google Scholar] [CrossRef] [Green Version]
- Cohen, J.D.; Brinton, E.A.; Ito, M.K.; Jacobson, T.A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 2012, 6, 208–215. [Google Scholar] [CrossRef] [Green Version]
- Calza, L. Long-term use of rosuvastatin: A critical risk benefit appraisal and comparison with other antihyperlipidemics. Drug Healthc. Patient Saf. 2009, 1, 25–33. [Google Scholar] [CrossRef] [Green Version]
- Olsson, A.G.; Istad, H.; Luurila, O.; Ose, L.; Stender, S.; Tuomilehto, J.; Wiklund, O.; Southworth, H.; Pears, J.; Wilpshaar, J.W.; et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J. 2002, 144, 1044–1051. [Google Scholar] [CrossRef] [PubMed]
- Olsson, A.G.; Pears, J.; McKellar, J.; Mizan, J.; Raza, A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. 2001, 88, 504–508. [Google Scholar] [CrossRef] [PubMed]
- Saku, K.; Zhang, B.; Noda, K.; Investigators, P.T. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ. J. 2011, 75, 1493–1505. [Google Scholar] [CrossRef] [Green Version]
- Jones, P.H.; Davidson, M.H.; Stein, E.A.; Bays, H.E.; McKenney, J.M.; Miller, E.; Cain, V.A.; Blasetto, J.W.; Group, S.S. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 2003, 92, 152–160. [Google Scholar] [CrossRef]
- Zhang, L.; Zhang, S.; Yu, Y.; Jiang, H.; Ge, J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol: A meta-analysis of trials with East Asian populations. Herz 2020, 45, 594–602. [Google Scholar] [CrossRef]
- Alsheikh-Ali, A.A.; Ambrose, M.S.; Kuvin, J.T.; Karas, R.H. The safety of rosuvastatin as used in common clinical practice: A postmarketing analysis. Circulation 2005, 111, 3051–3057. [Google Scholar] [CrossRef] [Green Version]
- Vavlukis, M.; Mladenovska, K.; Daka, A.; Dimovski, A.; Domazetovska, S.; Kuzmanovska, S.; Kedev, S. Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a). Ann. Pharm. 2016, 50, 609–615. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Castellano, J.M.; Pocock, S.J.; Bhatt, D.L.; Quesada, A.J.; Owen, R.; Fernandez-Ortiz, A.; Sanchez, P.L.; Marin Ortuno, F.; Vazquez Rodriguez, J.M.; Domingo-Fernandez, A.; et al. Polypill Strategy in Secondary Cardiovascular Prevention. N. Engl. J. Med. 2022, 387, 967–977. [Google Scholar] [CrossRef] [PubMed]
Patient Characteristics | Value |
---|---|
Age, median (IQR), years | 62.0 (56.0–67.0) |
Sex, male, n (%) | 1196 (76.2) |
Body mass index, median (IQR), kg/m2 | 28.1 (25.7–31.1) |
Comorbidity | |
At least one coexisting condition, n (%) | 1539 (98.0) |
Cardiovascular risk factors | |
Arterial hypertension, n (%) | 1148 (73.1) |
Familial hypercholesterolemia, n (%) | 121 (7.7) |
Heterozygous familial hypercholesterolemia | 111 (91.7) |
Homozygous familial hypercholesterolemia | 10 (8.3) |
Chronic kidney disease, n (%) | 132 (8.4) |
Mean eGFR, mL/min/1.73 m2 (SD) | 43.8 (12.8) |
Microalbuminuria, n (%) | 163 (10.4) |
Diabetes mellitus, n (%) | 545 (34.7) |
Type 1, n (%) | 23 (4.2) |
Mean duration since diagnosis, years (SD) | 22.5 (14.5) |
Type 2, n (%) | 522 (95.8) |
Mean duration since diagnosis, years (SD) | 9.1 (6.5) |
Retinopathy, n (%) | 79 (5) |
Neuropathy, n (%) | 45 (2.9) |
Current smoker, n (%) | 450 (28.7) |
Cardiovascular disease/events, n (%) | 1216 (77.5) |
Coronary heart disease | 686 (56.4) |
Myocardium infarction | 417 (34.3) |
Stroke | 42 (3.5) |
Peripheral arterial disease | 41 (3.4) |
Cardiac valve disease | 19 (1.6) |
Others | 11 (0.9) |
SCORE, median (IQR) 1 | 4 (2–9) |
Cardiovascular risk (2019 ESC/EAS guidelines), n (%) 2 | |
Very high risk | 1271 (85.8) |
High risk | 78 (5.3) |
Moderate risk | 121 (8.2) |
Low risk | 12 (0.8) |
Treatment | Last Treatment n = 1570 n (%) | Cardiovascular Risk | Prior Treatment n = 578 n (%) | p-Value Last vs. Prior Treatment 1 | ||
---|---|---|---|---|---|---|
Low-Moderate Risk n = 133 n (%) | High Risk n = 78 n (%) | Very High Risk n = 1271 n (%) | ||||
Rosuvastatin, n (%) | 175 (11.1) | 27 (20.3) | 10 (12.8) | 117 (9.2) | 127 (22.0) | <0.001 |
20 mg, n (%) | 167 (10.6) | 27 (20.3) | 10 (12.8) | 109 (8.6) | 121 (20.9) | <0.001 |
40 mg, n (%) | 8 (0.5) | 0 (0.0) | 0 (0.0) | 8 (0.6) | 6 (1.0) | 0.177 |
Rosuvastatin + Ezetimibe, n (%) | 644 (41.0) | 47 (35.3) | 35 (44.9) | 529 (41.6) | 23 (3.9) | <0.001 |
20 mg + 10 mg, n (%) | 571 (36.4) | 36 (27.1) | 31 (39.7) | 474 (37.3) | 21 (3.6) | <0.001 |
40 mg + 10 mg, n (%) | 73 (4.6) | 11 (8.3) | 4 (5.1) | 55 (4.3) | 2 (0.3) | <0.001 |
Atorvastatin, n (%) | 420 (26.8) | 40 (30.1) | 24 (30.8) | 332 (26.1) | 381 (65.9) | <0.001 |
40 mg, n (%) | 236 (15.0) | 32 (24.1) | 16 (20.5) | 166 (13.1) | 251 (43.4) | <0.001 |
80 mg, n (%) | 184 (11.7) | 8 (6.0) | 8 (10.3) | 166 (13.1) | 130 (22.5) | <0.001 |
Atorvastatin + Ezetimibe, n (%) | 331 (21.1) | 19 (14.3) | 9 (11.5) | 293 (23.1) | 47 (8.1) | <0.001 |
40 mg + 10 mg, n (%) | 136 (8.6) | 11 (8.3) | 6 (7.7) | 111 (8.7) | 36 (6.2) | 0.065 |
80 mg + 10 mg, n (%) | 195 (12.4) | 8 (6.0) | 3 (3.8) | 182 (14.3) | 11 (1.9) | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barrios, V.; Pintó, X.; Escobar, C.; Varona, J.F.; Gámez, J.M. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study. J. Clin. Med. 2023, 12, 3187. https://doi.org/10.3390/jcm12093187
Barrios V, Pintó X, Escobar C, Varona JF, Gámez JM. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study. Journal of Clinical Medicine. 2023; 12(9):3187. https://doi.org/10.3390/jcm12093187
Chicago/Turabian StyleBarrios, Vivencio, Xavier Pintó, Carlos Escobar, Jose F. Varona, and José M. Gámez. 2023. "Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study" Journal of Clinical Medicine 12, no. 9: 3187. https://doi.org/10.3390/jcm12093187